Bernard emphasized strong performances in the QIAstat Diagnostics and QuantiFERON portfolios, with QIAstat achieving 25% CER growth in Q4 and over 660 new system placements in 2024. QuantiFERON grew ...

The German premium car maker is expanding its product portfolio after an inventory reduction it conducted in the fourth ...

We predict UPS stock will continue downward trend in 2025 despite cost-cutting measures, with the potential for sentiment ...

Kikkoman has a solid balance sheet, in our view, as the company sits on strong cash balance with minimal debt. The company’s debt/equity ratio is lower than domestic and international peers, following ...